In the realm of laboratory automation and innovation, Beckman Coulter Life Sciences, a distinguished entity under the Danaher umbrella, has recently introduced a groundbreaking advancement. The launch of the IR820 and IR870 infrared dye antibody conjugates marks a pivotal moment for research flow cytometry labs worldwide. These novel conjugates offer a unique solution characterized by low noise levels, single laser excitation, minimal dye interferences, negligible overlap with other fluorochrome emissions, and an exceptionally low autofluorescence background.
The IR820 and IR870 reagents stand out as the industry’s first directly conjugated antibodies tailored for infrared excitation. With their unparalleled characteristics, these reagents are particularly well-suited for lineage marker staining, providing remarkable brightness to facilitate the clear identification of gating antigens. Furthermore, their design ensures that the detection of non-infrared dyes remains uncompromised, thanks to the near-complete absence of spectral overlap. This breakthrough enables researchers to incorporate lineage gating markers more effectively into their antibody panels, thereby enhancing the quality and flexibility of high-parameter flow cytometry experiments.
As the field of high-parameter flow cytometry continues to evolve and gain prominence, the significance of meticulous antibody panel design cannot be overstated. The complexity of spectral interference patterns poses a significant challenge to data quality, emphasizing the critical role of innovations like the IR820 and IR870 infrared dye conjugates. By simplifying the experimental landscape and elevating the infrared spectral range to a premier position for lineage markers, Beckman Coulter empowers researchers to delve into new frontiers of human phenotyping experiments with unprecedented clarity and precision.
Traditionally, flow cytometry fluorochrome conjugates have not encompassed the infrared range, a limitation that has constrained the effective delineation of major subpopulations and their functional status. The proximity of lineage markers and probes for weak co-expressed antigens within the same spectral ranges has historically hindered the resolution and sensitive detection of dimmer companion antigens. However, the advent of the IR820 and IR870 conjugates heralds a transformative shift in this paradigm, offering researchers a novel tool to overcome these challenges and enhance the depth and accuracy of their analyses.
Pietro Lopriore, the Vice President and General Manager of the Flow Cytometry Business Unit at Beckman Coulter, emphasized the pivotal role of these infrared dye conjugates in streamlining antibody panel design and optimizing data acquisition in high-dimensional flow cytometry experiments. By alleviating complexities and enhancing clarity, these conjugates pave the way for a more nuanced and comprehensive understanding of complex cellular phenotypes and immune responses, propelling scientific inquiry into uncharted territories.
In a recent validation study conducted by Dr. Theo Gerdener, Head of Immune Phenotyping at ABJ Oncology in Pretoria, South Africa, the CD3 IR820 infrared flow cytometry antibody demonstrated remarkable efficacy and precision. Dr. Gerdener’s endorsement underscores the transformative impact of these infrared dye conjugates in expanding the horizons of flow cytometry panels, enabling the inclusion of rare markers and facilitating the exploration of intricate cellular landscapes with unprecedented detail and resolution.
The integration of the IR820 and IR870 infrared dye conjugates into the Beckman Coulter Life Sciences reagent portfolio heralds a new era of possibilities for users of IR-equipped CytoFLEX LX and S instruments. These non-tandem dyes, optimized for excitation at 808 nm and emission at 835 and 896 nm, offer a seamless extension of human phenotyping experiments into the infrared spectral range. With specificities targeting CD3, CD4, CD8, CD14, CD20, and CD45, these Research Use Only reagents adhere to stringent manufacturing practices, ensuring reliability and reproducibility in diverse research settings.
In conclusion, Beckman Coulter’s pioneering initiative in launching the IR820 and IR870 infrared dye antibody conjugates represents a significant leap forward in the realm of flow cytometry and human phenotyping experiments. By providing researchers with a cutting-edge tool to navigate the complexities of high-dimensional data acquisition and analysis, these conjugates empower scientific exploration and discovery in unprecedented ways. As the scientific community embraces these innovations and integrates them into their research workflows, the landscape of cellular phenotyping and immune profiling is poised to undergo a profound transformation, unlocking new insights and advancing our understanding of human health and disease.
Takeaways:
– The introduction of IR820 and IR870 infrared dye antibody conjugates by Beckman Coulter revolutionizes high-parameter flow cytometry experiments.
– These industry-first conjugates offer superior brightness, reduced spectral overlap, and enhanced clarity for lineage marker staining in complex antibody panels.
– Researchers can now delve into human phenotyping experiments with unprecedented precision and flexibility, thanks to the unique capabilities of these infrared dye conjugates.
– The integration of IR820 and IR870 into the Beckman Coulter reagent portfolio opens up new possibilities for exploring cellular phenotypes and immune responses in the infrared spectral range.
– By leveraging these innovative conjugates, scientists can elevate the quality and depth of their flow cytometry analyses, paving the way for groundbreaking discoveries in immunology and beyond.
Tags: automation
Read more on news-medical.net